1
|
Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence. Sci Rep 2021; 11:16505. [PMID: 34389744 PMCID: PMC8363632 DOI: 10.1038/s41598-021-95355-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Accepted: 07/06/2021] [Indexed: 11/08/2022] Open
Abstract
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. The two predominant histologic variants of RMS, embryonal and alveolar rhabdomyosarcoma (eRMS and aRMS, respectively), carry very different prognoses. While eRMS is associated with an intermediate prognosis, the 5-year survival rate of aRMS is less than 30%. The RMS subtypes are also different at the molecular level-eRMS frequently has multiple genetic alterations, including mutations in RAS and TP53, whereas aRMS often has chromosomal translocations resulting in PAX3-FOXO1 or PAX7-FOXO1 fusions, but otherwise has a "quiet" genome. Interestingly, mutations in RAS are rarely found in aRMS. In this study, we explored the role of oncogenic RAS in aRMS. We found that while ectopic oncogenic HRAS expression was tolerated in the human RAS-driven eRMS cell line RD, it was detrimental to cell growth and proliferation in the human aRMS cell line Rh28. Growth inhibition was mediated by oncogene-induced senescence and associated with increased RB pathway activity and expression of the cyclin-dependent kinase inhibitors p16 and p21. Unexpectedly, the human eRMS cell line RMS-YM, a RAS wild-type eRMS cell line, also exhibited growth inhibition in response to oncogenic HRAS in a manner similar to aRMS Rh28 cells. This work suggests that oncogenic RAS is expressed in a context-dependent manner in RMS and may provide insight into the differential origins and therapeutic opportunities for RMS subtypes.
Collapse
|
2
|
Cobbers JL, Wolter M, Reifenberger J, Ring GU, Jessen F, An H, Niederacher D, Schmidt EE, Ichimura K, Floeth F, Kirsch L, Borchard F, Louis DN, Collins VP, Reifenberger G. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 2006; 8:263-76. [PMID: 9546285 PMCID: PMC8098352 DOI: 10.1111/j.1750-3639.1998.tb00152.x] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Twenty primary central nervous system lymphomas (PCNSL) from immunocompetent patients (nineteen B-cell lymphomas and one T-cell lymphoma) were investigated for genetic alterations and/or expression of the genes BCL2, CCND1, CDK4, CDKN1A, CDKN2A, MDM2, MYC, RB1, REL, and TP53. The gene found to be altered most frequently was CDKN2A. Eight tumors (40%) showed homozygous and two tumors (10%) hemizygous CDKN2A deletions. Furthermore, methylation analysis of six PCNSL without homozygous CDKN2A loss revealed methylation of the CpG island within exon 1 of CDKN2A in three instances. Reverse transcription PCR analysis of CDKN2A mRNA expression was performed for 11 tumors and showed either no or weak signals. Similarly, immunocytochemistry for the CDKN2A gene product (p16) remained either completely negative or showed expression restricted to single tumor cells. None of the PCNSL showed amplification of CDK4. Similarly, investigation of CCND1 revealed no amplification, rearrangement or overexpression. The retinoblastoma protein was strongly expressed in all tumors. Only one PCNSL showed a mutation of the TP53 gene, i.e., a missense mutation at codon 248 (CGG to TGG:Arg to Trp). No evidence of BCL2 gene rearrangement was found in 11 tumors investigated. The bcl-2 protein, however, was strongly expressed in most tumors. None of the 20 PCNSL demonstrated gene amplification of MDM2, MYC or REL. In summary, inactivation of CDKN2A by either homozygous deletion or DNA methylation represents an important molecular mechanism in PCNSL. Mutation of the TP53 gene and alterations of the other genes investigated appear to be of minor significance in these tumors.
Collapse
Affiliation(s)
| | - Marietta Wolter
- Departments of Neuropathology, Heinrich‐Heine‐Universität, Düsseldorf, Germany
| | | | - Gudrun U. Ring
- Departments of Neuropathology, Heinrich‐Heine‐Universität, Düsseldorf, Germany
| | - Frank Jessen
- Departments of Neuropathology, Heinrich‐Heine‐Universität, Düsseldorf, Germany
| | - Han‐Xiang An
- Gynecology, Heinrich‐Heine‐Universität, Düsseldorf, Germany
- Center for Biological and Medical Research (BMFZ), Heinrich‐Heine‐Universität, Düsseldorf, Germany
| | - Dieter Niederacher
- Gynecology, Heinrich‐Heine‐Universität, Düsseldorf, Germany
- Center for Biological and Medical Research (BMFZ), Heinrich‐Heine‐Universität, Düsseldorf, Germany
| | - Esther E. Schmidt
- Institute for Oncology and Pathology, Division of Tumor Pathology, and Ludwig Institute for Cancer Research, Stockholm Branch, Karolinska Hospital, Stockholm, Sweden
| | - Koichi Ichimura
- Institute for Oncology and Pathology, Division of Tumor Pathology, and Ludwig Institute for Cancer Research, Stockholm Branch, Karolinska Hospital, Stockholm, Sweden
| | - Frank Floeth
- Neurosurgery, Heinrich‐Heine‐Universität, Düsseldorf, Germany
| | - Lutz Kirsch
- Neurosurgical Clinic, Evangelische‐und‐Johanniter‐Krankenanstalten Duisburg‐Nord/Oberhausen, Germany
| | - Franz Borchard
- Pathology, Heinrich‐Heine‐Universität, Düsseldorf, Germany
| | - David N. Louis
- Molecular Neuro‐Oncology Laboratory, Department of Pathology (Neuropathology) and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA
| | - V. Peter Collins
- Institute for Oncology and Pathology, Division of Tumor Pathology, and Ludwig Institute for Cancer Research, Stockholm Branch, Karolinska Hospital, Stockholm, Sweden
| | - Guido Reifenberger
- Departments of Neuropathology, Heinrich‐Heine‐Universität, Düsseldorf, Germany
- Center for Biological and Medical Research (BMFZ), Heinrich‐Heine‐Universität, Düsseldorf, Germany
| |
Collapse
|
3
|
Abstract
Robertsonian translocations are the most common constitutional structural abnormalities but are rarely reported as acquired aberrations in hematologic malignancies. The nonhomologous acrocentric rearrangements are designated as Robertsonian translocations, whereas the homologous acrocentric rearrangements are referred to as isochromosomes. Robertsonian rearrangements have the highest mutation rates of structural chromosome rearrangements based on surveys of newborns and spontaneous abortions. It would be expected that Robertsonian recombinations would be more common than suggested by the literature. A survey of the cytogenetics database from a single institution found 17 patients with acquired Robertsonian rearrangement and hematologic malignancies. This is combined with data from the literature for a total of 237 patients. All of the possible types of Robertsonian rearrangements have been reported in hematologic malignancies, with the i(13q), i(14q), and i(21q) accounting for nearly 60%. Complex karyotypic changes are seen in the majority of cases, corresponding with disease evolution. These karyotypes consistently show loss of chromosomes 5 and/or 7 in the myelocytic disorders, nonacrocentric isochromosomes, and centromeric breakage and reunion. However, nearly 25% of the acquired rearrangements were found as the sole abnormality or in addition to an established cytogenetic aberration. Most of these were the i(14q) with the myelodysplasia subtypes refractory anemia and chronic myelomonocytic leukemia.
Collapse
Affiliation(s)
- Jeanna Welborn
- Department of Internal Medicine and Pathology, University of California at Davis Medical Center Cancer Center, Room 3017, 4501 X Street, Sacramento, CA 95817 USA.
| |
Collapse
|